Fennec Announces Results of Annual Meeting
Stocks in this Quantisnow insightHealth Care
Historical context for FENC
Across the 21 sessions after earlier FENC headlines, the stock closed higher 10 times and lower 10 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | FENC | SPY |
|---|---|---|---|
| May 22, 2026 | Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting | -0.4% | +0.4% |
| May 19, 2026 | Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +1.7% | -0.7% |
| May 14, 2026 | Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | +36.5% | +0.8% |
| May 7, 2026 | Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 | -3.9% | -0.3% |
| Apr 22, 2026 | Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting | +2.1% | +1.0% |
| Apr 7, 2026 | Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center | -1.6% | +0.0% |
Quantisnow market dataNASDAQ
FENC
Fennec Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
Get push alerts for FENC
Full FENC profile on Quantisnow Follow FENC and get a push notification the moment its next story breaks.